New Millennium Group LLC Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

New Millennium Group LLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 207,063 shares of the biotechnology company's stock, valued at approximately $4,139,000. ADMA Biologics comprises about 2.7% of New Millennium Group LLC's investment portfolio, making the stock its 12th biggest holding. New Millennium Group LLC owned approximately 0.09% of ADMA Biologics as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in ADMA. Assenagon Asset Management S.A. raised its stake in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after buying an additional 92,281 shares in the last quarter. Seven Eight Capital LP acquired a new position in ADMA Biologics in the 2nd quarter valued at $1,992,000. Principal Financial Group Inc. raised its stake in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after purchasing an additional 1,059,394 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $2,253,000. Finally, Point72 Asset Management L.P. purchased a new stake in ADMA Biologics during the 2nd quarter worth approximately $1,157,000. 75.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company's stock, valued at approximately $7,589,587.20. The trade was a 5.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 10.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 466,900 shares of company stock valued at $8,224,121. Company insiders own 3.70% of the company's stock.

ADMA Biologics Stock Up 5.6 %

ADMA traded up $1.09 during trading on Tuesday, hitting $20.63. The company had a trading volume of 2,200,298 shares, compared to its average volume of 3,656,222. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm's 50-day moving average price is $18.57 and its 200 day moving average price is $14.54. The company has a market capitalization of $4.88 billion, a PE ratio of 71.25 and a beta of 0.64. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the firm posted $0.01 earnings per share. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ADMA. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Finally, Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.